Emergency Department Buprenorphine Trial: Abstract Report

Key Takeaways

• A randomized emergency department trial compared extended-release injectable vs sublingual buprenorphine, not referral-based care.
• Treatment engagement at 7 days was similar between groups (40.5% vs 38.5%), with no significant difference.
• Safety outcomes were comparable, and extended-release buprenorphine showed advantages in some secondary measures (e.g., craving, illicit use, satisfaction).

The framing centers on whether the formulation and delivery of medication initiated during acute care are associated with treatment engagement after patients leave the emergency setting. The randomized design places two pharmacologic approaches side by side in a population presenting for emergency treatment. At its core, the trial addresses short-term treatment engagement following ED-initiated therapy.

Investigators compared randomized care pathways for patients with opioid use disorder seen in the emergency department. Both pathways involved initiating buprenorphine during the visit, differing in formulation (extended-release injectable vs sublingual). The description keeps attention on how these approaches performed in supporting subsequent treatment engagement. The population and setting keep the comparison focused on the transition from acute care to ongoing management, with both groups receiving active medication treatment rather than referral alone.

The authors note that treatment engagement at 7 days was the primary outcome. At day 7, engagement rates were similar between groups (40.5% with extended-release buprenorphine vs 38.5% with sublingual buprenorphine), indicating no statistically significant difference. Researchers also assessed outcomes at 30 days, where engagement remained comparable between groups. These findings indicate similar short-term effectiveness for both formulations in maintaining treatment engagement after ED initiation.

Secondary outcomes extended beyond engagement to include safety and patient-centered measures. Rates of precipitated withdrawal and overdose were low and similar between groups. Extended-release buprenorphine was associated with lower craving scores, fewer days of illicit opioid use, and slightly higher treatment satisfaction. These additional findings provide context beyond the primary endpoint while maintaining the focus on early post-discharge outcomes.

The investigators examined whether differences in formulation and delivery of ED-initiated buprenorphine were associated with different post-discharge experiences. In descriptive terms, the study asks whether a single-dose extended-release strategy performs differently from a daily sublingual regimen in supporting early treatment engagement and related outcomes. The trial’s results support comparable effectiveness between approaches, with some differences in secondary measures. The available source context supports a detailed description of the randomized ED comparison and the post-discharge outcomes it set out to assess.